We are interested in developing new therapeutic strategies to improve outcomes for blood cancer patients. We aim to contribute along each stage of the biomedical research spectrum - from understanding fundamental oncogenic processes to identifying novel drug targets and investigating why cancer cells become resistant to established treatments. We use model systems and advanced molecular and functional genomic approaches to study how genetic events that are known to occur in human cancer alter the properties of blood cells. We are particularly interested in metabolic and epigenetic pathways that underpin cancer development and evolution.